Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

tags : Phase 2    source : Www.anaptysbio.com    save search

Imsidolimab, an Anti-IL-36 Receptor Monoclonal Antibody, in the Treatment of Generalized Pustular Psoriasis: Results from a Phase 2 Trial
Published: 2021-10-26 (Crawled : 20:00) - anaptysbio.com
ANAB | $19.865 0.18% 0.18% 290K twitter stocktwits trandingview |
Health Technology
| | O: 5.47% H: 2.32% C: 0.23%

psoriasis treatment phase 2 results antibody trial
Gainers vs Losers
57% 43%

Top 10 Gainers
AGBA | News | $1.305 226.25% 130M twitter stocktwits trandingview |
Finance

EGOX | $0.0515 43.06% 30.1% 330M twitter stocktwits trandingview |

PAPL | $1.435 -12.5% 1.1M twitter stocktwits trandingview |

ZCMD | $1.87 28.97% 22.46% 31M twitter stocktwits trandingview |
Commercial Services

NVFY | $2.65 25.59% 33M twitter stocktwits trandingview |
Consumer Durables

INSG | $3.03 25.21% 330K twitter stocktwits trandingview |
Electronic Technology

KNW 4 | $0.59 -0.71% 18.64% 27K twitter stocktwits trandingview |
Manufacturing

GCTK | $0.8191 22.25% 18.2% 190K twitter stocktwits trandingview |
Manufacturing

ASNS | $0.828 21.75% 17.86% 18K twitter stocktwits trandingview |

UONE | $2.36 19.8% 16.53% 75K twitter stocktwits trandingview |
Consumer Services


Your saved searches
Save your searches and get alerts when important news are released.